SJ733 + Cobicistat

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malaria

Conditions

Malaria

Trial Timeline

Mar 1, 2016 → Mar 9, 2018

About SJ733 + Cobicistat

SJ733 + Cobicistat is a phase 1 stage product being developed by Eisai for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT02661373. Target conditions include Malaria.

What happened to similar drugs?

11 of 19 similar drugs in Malaria were approved

Approved (11) Terminated (1) Active (8)
🔄KLU156 + CoartemNovartisPhase 3
🔄Artemether-lumefantrineNovartisPhase 3
🔄Artemether-lumefantrineNovartisPhase 3
COA566NovartisApproved
Co-artemetherNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02661373Phase 1Completed